Short- and long-term efficacy of modified directly-observed antiretroviral treatment in Mombasa, Kenya: A randomised trial
Sarna,Avina; Luchters,Stanley; Geibel,Scott; Chersich,Matthew F.; Munyao,Paul; Kaai,Susan; Mandaliya,Kishorchandra N.; Shikely,Khadija; Temmerman,Marleen; Rutenberg,Naomi
Journal of Acquired Immune Deficiency Syndromes 48(5): 611-619
Publication date: 2008
To determine short- and long-term efficacy of modified directly observed therapy (m-DOT) on antiretroviral adherence.
Randomized controlled trial.
Setting and analytic approach
From September 2003 to November 2004, 234 HIV-infected adults were assigned m-DOT (24 weeks of twice weekly health center visits for nurse-observed pill ingestion, adherence support, and medication collection) or standard care. Follow-up continued until week 72. Self-reported and pill-count adherence and, secondarily, viral suppression and body mass index measures are reported. Generalized estimating equations adjusted for intraclient clustering and covariates were used.
During weeks 1-24, 9.1 percent (9/99) of m-DOT participants reported missing doses compared with 19.1 percent (20/105) of controls (P = 0.04) and 96.5 percent (517/571) of m-DOT pill-count measures were = 95 percent compared with 86.1 percent (445/517) in controls [adjusted odds ratio = 4.4; 95% confidence interval (CI) = 2.6-7.5; P < 0.001]. Adherence with m-DOT was 4.8 times greater (95% CI = 2.7-8.6; P < 0.001) with adjustment for depression and HIV-related hospitalization. In weeks 25-48, adherence with m-DOT (488/589) was similar to controls (507/630). Viral suppression at 48 weeks was 2.0 times (95% CI = 0.8-5.2; P = 0.13) as likely in m-DOT participants as controls. M-DOT patients had larger body mass index increases at 24 weeks (2.2 vs. 1.4 kg/m3; P = 0.014). Viral suppression was more likely at week 48 (21/25 vs. 13/22; P = 0.057) and week 72 (27/30 vs. 15/23; P = 0.027) among depressed participants receiving m-DOT.
M-DOT increased adherence, most notably among depressed participants.